ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,881Medicare Part D Prescriptions Filled, Including Refills

Rank: 244 out of 1000

$403K Total Retail Price of All Prescriptions

Rank: 348 out of 1000

268 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
54% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

17% of this provider’s 268 patients filled at least one prescription for a schedule three drug, compared to an average of 20%.

Risky Drugs to Seniors

2% of this provider’s 8,946 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$37 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

41 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
SIMVASTATIN 525 445 1 3
OMEPRAZOLE 357 292 2 2
LEVOTHYROXINE SODIUM 304 267 3 4
ATENOLOL 296 256 4 24
GABAPENTIN 258 179 5 11
AMLODIPINE BESYLATE 253 243 6 6
WARFARIN SODIUM 242 207 7 22
METFORMIN HCL ER 237 192 8 44
FUROSEMIDE 235 211 9 7
LISINOPRIL 233 210 10 5
HYDROCODONE-ACETAMINOPHEN 215 94 S3 11 1
BENAZEPRIL HCL 205 158 12 61
TRIAMTERENE-HCTZ 199 168 13 48
POTASSIUM CHLORIDE 191 188 14 10
TRAMADOL HCL 170 130 15 13
TRAZODONE HCL 158 140 16 29
SERTRALINE HCL 154 126 17 26
INDAPAMIDE 152 140 18 164
ATENOLOL-CHLORTHALIDONE 147 135 19 206
GLIMEPIRIDE 142 118 20 34
NEXIUM 141 132 21 23
FLUOXETINE HCL 135 95 22 51
ATORVASTATIN CALCIUM 130 123 23 18
BISOPROLOL-HYDROCHLOROTHIAZIDE 125 80 24 101
CARVEDILOL 114 84 25 15
METFORMIN HCL 112 98 26 8
MELOXICAM 112 105 26 14
ENALAPRIL MALEATE 111 87 28 58
ALLOPURINOL 110 98 29 31
ZOLPIDEM TARTRATE 96 75 30 16
LOVASTATIN 95 94 31 41
PANTOPRAZOLE SODIUM 94 92 32 28
RANITIDINE HCL 89 67 33 37
DONEPEZIL HCL 87 64 34 32
CITALOPRAM HBR 84 79 35 17
FLUTICASONE PROPIONATE 82 50 36 40
PRENATAL PLUS 82 70 36 242
PRAVASTATIN SODIUM 81 70 38 12
ALENDRONATE SODIUM 79 56 39 57
LOSARTAN POTASSIUM 78 78 40 25
METOPROLOL TARTRATE 72 71 41 19
TAMSULOSIN HCL 67 40 42 33
SPIRIVA 63 59 43 64
DILTIAZEM ER 60 37 44 146
SPIRONOLACTONE 58 58 45 78
METOCLOPRAMIDE HCL 57 44 46 99
CELEBREX 55 27 47 98
HYDROCHLOROTHIAZIDE 55 50 47 9
COLCRYS 55 55 47 171
AMITRIPTYLINE HCL 54 38 R 50 45
TRIMETHOPRIM 51 41 51 442
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.